AVB-S6-500/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of
AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in
patients with platinum resistant recurrent ovarian cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Aravive, Inc.
Collaborators:
European Network of Gynaecological Oncological Trial Groups (ENGOT) GOG Foundation